title: A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
abstract: OBJECTIVE
  Treatment with ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency. The aim of this study was to assess the cost-effectiveness of ferric carboxymaltose treatment vs no treatment in these patients.
  
  
  METHODS
  We used an economic model based on the Spanish National Health System, with a time horizon of 24 weeks. Patient characteristics and ferric carboxymaltose effectiveness (quality-adjusted life years) were taken from the Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure trial. Health care resource use and unit costs were taken either from Spanish sources, or from the above mentioned trial.
  
  
  RESULTS
  In the base case analysis, patients treated with and without ferric carboxymaltose treatment acquired 0.335 and 0.298 quality-adjusted life years, respectively, representing a gain of 0.037 quality-adjusted life years for each treated patient. The cost per patient was €824.17 and €597.59, respectively, resulting in an additional cost of €226.58 for each treated patient. The cost of gaining 1 quality adjusted life year with ferric carboxymaltose was €6123.78. Sensitivity analyses confirmed the robustness of the model. The probability of ferric carboxymaltose being cost-effective (< €30 000 per quality-adjusted life year) and dominant (more effective and lower cost than no treatment) was 93.0% and 6.6%, respectively.
  
  
  CONCLUSIONS
  Treatment with ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, is cost-effective in Spain.
authors: Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain; Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain. Electronic address: jcomin@hospitaldelmar.cat.
authors: Josep
authors: J
authors: Comín-Colet
authors: Health Value, Madrid, Spain.
authors: Darío
authors: D
authors: Rubio-Rodríguez
authors: Health Value, Madrid, Spain.
authors: Carlos
authors: C
authors: Rubio-Terrés
authors: Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain; Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.
authors: Cristina
authors: C
authors: Enjuanes-Grau
authors: Institute of Pharmaceutical Medicine/ECPM, University of Basel, Basel, Switzerland.
authors: Florian S
authors: FS
authors: Gutzwiller
authors: Department of Cardiology, Virchow-Klinikum, Charité Universitätsmedizin, Berlin, Germany.
authors: Stefan D
authors: SD
authors: Anker
authors: Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
authors: Piotr
authors: P
authors: Ponikowski
mesh_terms: D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D005290:Ferric Compounds / Q000191:economics / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008320:Maltose / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology
chemical_list: D005290:Ferric Compounds; C522335:ferric carboxymaltose; D008320:Maltose
keywords: Anemia; Análisis coste-efectividad; Cost-effectiveness analysis; Deficiencia de hierro; Ferric carboxymaltose; Heart failure; Hierro carboximaltosa; Insuficiencia cardiaca; Iron deficiency